0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global α-Glucosidase Inhibitors Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-1F18502
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global α Glucosidase Inhibitors Market Research Report 2024
BUY CHAPTERS

Global α-Glucosidase Inhibitors Market Research Report 2024

Code: QYRE-Auto-1F18502
Report
October 2024
Pages:108
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

α-Glucosidase Inhibitors Market Size

The global α-Glucosidase Inhibitors market was valued at US$ 881 million in 2023 and is anticipated to reach US$ 1198 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.

α-Glucosidase Inhibitors Market

α-Glucosidase Inhibitors Market

α-Glucosidase inhibitors are a class of oral medications designed to manage type 2 diabetes by slowing carbohydrate digestion and absorption in the intestine.Common examples include acarbose ,Voglibose and miglitol, which are often used in conjunction with other diabetes medications to enhance blood sugar management and reduce postprandial glucose spikes.
The development of α-glucosidase inhibitors has evolved significantly since their introduction in the 1990s, reflecting advancements in diabetes management and a deeper understanding of their clinical applications. These drugs, including agents like acarbose and miglitol, work by inhibiting the enzymes responsible for breaking down carbohydrates in the intestines, thereby slowing glucose absorption and reducing postprandial blood sugar spikes. Initially, they were valued for their ability to control postprandial hyperglycemia, offering an additional tool for managing type 2 diabetes alongside more traditional therapies.
In recent years, the focus has shifted towards optimizing the use of α-glucosidase inhibitors in combination with other antidiabetic agents. Research has increasingly highlighted their role in comprehensive diabetes management, particularly in conjunction with metformin, sulfonylureas, or insulin. Studies have demonstrated that combining α-glucosidase inhibitors with other medications can enhance overall glycemic control and potentially offer benefits such as improved weight management and reduced risk of cardiovascular complications. This trend reflects a growing emphasis on personalized medicine and the need for multi-faceted treatment approaches to address the complex nature of diabetes.
Looking ahead, the development trend for α-glucosidase inhibitors is expected to continue focusing on their integration with emerging therapies and technological advancements. As new classes of diabetes medications and advanced drug delivery systems are developed, α-glucosidase inhibitors may be combined with these innovations to create more effective and patient-friendly treatment regimens. Additionally, ongoing research is likely to explore their role in managing diabetes-related complications and their potential benefits in different patient populations, such as those with prediabetes or metabolic syndrome. This evolving landscape aims to enhance the therapeutic efficacy and quality of life for individuals managing type 2 diabetes.

Report Scope

This report aims to provide a comprehensive presentation of the global market for α-Glucosidase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding α-Glucosidase Inhibitors.
The α-Glucosidase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global α-Glucosidase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the α-Glucosidase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of α-Glucosidase Inhibitors Market Report

Report Metric Details
Report Name α-Glucosidase Inhibitors Market
Accounted market size in 2023 US$ 881 million
Forecasted market size in 2030 US$ 1198 million
CAGR 4.8%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Acarbose
  • Voglibose
  • Miglitol
  • Other
Segment by Application
  • Hospital and Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Bluepharma, Strides Pharma, Sun Pharmaceutical, Takeda, Pfizer, Lunan Pharma, SUN Pharma, Lupin Pharma, Glenmark Pharma, Shandong New Time Pharmaceutical, Weiao Pharmaceutical (Sichuan), Zhejiang Medicine, Cisen Pharmaceutical, Zhejiang Jingxin Pharmaceutical, Nanjing Hicin Pharmaceutical, Beijing SL Pharmaceutical, Jinri Pharmaceutical (China), Hangzhou East China Pharmaceutical, Zhejiang Hisun Pharmaceutical, CSPC Ouyi Pharmaceutical, Luye Pharma, Livzon Pharm, YaoPharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of α-Glucosidase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of α-Glucosidase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is α-Glucosidase Inhibitors Market growing?

Ans: The α-Glucosidase Inhibitors Market witnessing a CAGR of 4.8% during the forecast period 2024-2030.

What is the α-Glucosidase Inhibitors Market size in 2030?

Ans: The α-Glucosidase Inhibitors Market size in 2030 will be US$ 1198 million.

Who are the main players in the α-Glucosidase Inhibitors Market report?

Ans: The main players in the α-Glucosidase Inhibitors Market are Bayer, Bluepharma, Strides Pharma, Sun Pharmaceutical, Takeda, Pfizer, Lunan Pharma, SUN Pharma, Lupin Pharma, Glenmark Pharma, Shandong New Time Pharmaceutical, Weiao Pharmaceutical (Sichuan), Zhejiang Medicine, Cisen Pharmaceutical, Zhejiang Jingxin Pharmaceutical, Nanjing Hicin Pharmaceutical, Beijing SL Pharmaceutical, Jinri Pharmaceutical (China), Hangzhou East China Pharmaceutical, Zhejiang Hisun Pharmaceutical, CSPC Ouyi Pharmaceutical, Luye Pharma, Livzon Pharm, YaoPharma

What are the Application segmentation covered in the α-Glucosidase Inhibitors Market report?

Ans: The Applications covered in the α-Glucosidase Inhibitors Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the α-Glucosidase Inhibitors Market report?

Ans: The Types covered in the α-Glucosidase Inhibitors Market report are Acarbose, Voglibose, Miglitol, Other

1 α-Glucosidase Inhibitors Market Overview
1.1 Product Definition
1.2 α-Glucosidase Inhibitors by Type
1.2.1 Global α-Glucosidase Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Acarbose
1.2.3 Voglibose
1.2.4 Miglitol
1.2.5 Other
1.3 α-Glucosidase Inhibitors by Application
1.3.1 Global α-Glucosidase Inhibitors Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global α-Glucosidase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global α-Glucosidase Inhibitors Revenue 2019-2030
1.4.2 Global α-Glucosidase Inhibitors Sales 2019-2030
1.4.3 Global α-Glucosidase Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 α-Glucosidase Inhibitors Market Competition by Manufacturers
2.1 Global α-Glucosidase Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global α-Glucosidase Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global α-Glucosidase Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of α-Glucosidase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of α-Glucosidase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of α-Glucosidase Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of α-Glucosidase Inhibitors, Date of Enter into This Industry
2.8 Global α-Glucosidase Inhibitors Market Competitive Situation and Trends
2.8.1 Global α-Glucosidase Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest α-Glucosidase Inhibitors Players Market Share by Revenue
2.8.3 Global α-Glucosidase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global α-Glucosidase Inhibitors Market Scenario by Region
3.1 Global α-Glucosidase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global α-Glucosidase Inhibitors Sales by Region: 2019-2030
3.2.1 Global α-Glucosidase Inhibitors Sales by Region: 2019-2024
3.2.2 Global α-Glucosidase Inhibitors Sales by Region: 2025-2030
3.3 Global α-Glucosidase Inhibitors Revenue by Region: 2019-2030
3.3.1 Global α-Glucosidase Inhibitors Revenue by Region: 2019-2024
3.3.2 Global α-Glucosidase Inhibitors Revenue by Region: 2025-2030
3.4 North America α-Glucosidase Inhibitors Market Facts & Figures by Country
3.4.1 North America α-Glucosidase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America α-Glucosidase Inhibitors Sales by Country (2019-2030)
3.4.3 North America α-Glucosidase Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe α-Glucosidase Inhibitors Market Facts & Figures by Country
3.5.1 Europe α-Glucosidase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe α-Glucosidase Inhibitors Sales by Country (2019-2030)
3.5.3 Europe α-Glucosidase Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific α-Glucosidase Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific α-Glucosidase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific α-Glucosidase Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific α-Glucosidase Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America α-Glucosidase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America α-Glucosidase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America α-Glucosidase Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America α-Glucosidase Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa α-Glucosidase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa α-Glucosidase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa α-Glucosidase Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa α-Glucosidase Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global α-Glucosidase Inhibitors Sales by Type (2019-2030)
4.1.1 Global α-Glucosidase Inhibitors Sales by Type (2019-2024)
4.1.2 Global α-Glucosidase Inhibitors Sales by Type (2025-2030)
4.1.3 Global α-Glucosidase Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global α-Glucosidase Inhibitors Revenue by Type (2019-2030)
4.2.1 Global α-Glucosidase Inhibitors Revenue by Type (2019-2024)
4.2.2 Global α-Glucosidase Inhibitors Revenue by Type (2025-2030)
4.2.3 Global α-Glucosidase Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global α-Glucosidase Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global α-Glucosidase Inhibitors Sales by Application (2019-2030)
5.1.1 Global α-Glucosidase Inhibitors Sales by Application (2019-2024)
5.1.2 Global α-Glucosidase Inhibitors Sales by Application (2025-2030)
5.1.3 Global α-Glucosidase Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global α-Glucosidase Inhibitors Revenue by Application (2019-2030)
5.2.1 Global α-Glucosidase Inhibitors Revenue by Application (2019-2024)
5.2.2 Global α-Glucosidase Inhibitors Revenue by Application (2025-2030)
5.2.3 Global α-Glucosidase Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global α-Glucosidase Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer α-Glucosidase Inhibitors Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Bluepharma
6.2.1 Bluepharma Company Information
6.2.2 Bluepharma Description and Business Overview
6.2.3 Bluepharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bluepharma α-Glucosidase Inhibitors Product Portfolio
6.2.5 Bluepharma Recent Developments/Updates
6.3 Strides Pharma
6.3.1 Strides Pharma Company Information
6.3.2 Strides Pharma Description and Business Overview
6.3.3 Strides Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Strides Pharma α-Glucosidase Inhibitors Product Portfolio
6.3.5 Strides Pharma Recent Developments/Updates
6.4 Sun Pharmaceutical
6.4.1 Sun Pharmaceutical Company Information
6.4.2 Sun Pharmaceutical Description and Business Overview
6.4.3 Sun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.4.5 Sun Pharmaceutical Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Takeda α-Glucosidase Inhibitors Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Company Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer α-Glucosidase Inhibitors Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Lunan Pharma
6.7.1 Lunan Pharma Company Information
6.7.2 Lunan Pharma Description and Business Overview
6.7.3 Lunan Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Lunan Pharma α-Glucosidase Inhibitors Product Portfolio
6.7.5 Lunan Pharma Recent Developments/Updates
6.8 SUN Pharma
6.8.1 SUN Pharma Company Information
6.8.2 SUN Pharma Description and Business Overview
6.8.3 SUN Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 SUN Pharma α-Glucosidase Inhibitors Product Portfolio
6.8.5 SUN Pharma Recent Developments/Updates
6.9 Lupin Pharma
6.9.1 Lupin Pharma Company Information
6.9.2 Lupin Pharma Description and Business Overview
6.9.3 Lupin Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Lupin Pharma α-Glucosidase Inhibitors Product Portfolio
6.9.5 Lupin Pharma Recent Developments/Updates
6.10 Glenmark Pharma
6.10.1 Glenmark Pharma Company Information
6.10.2 Glenmark Pharma Description and Business Overview
6.10.3 Glenmark Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio
6.10.5 Glenmark Pharma Recent Developments/Updates
6.11 Shandong New Time Pharmaceutical
6.11.1 Shandong New Time Pharmaceutical Company Information
6.11.2 Shandong New Time Pharmaceutical Description and Business Overview
6.11.3 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.11.5 Shandong New Time Pharmaceutical Recent Developments/Updates
6.12 Weiao Pharmaceutical (Sichuan)
6.12.1 Weiao Pharmaceutical (Sichuan) Company Information
6.12.2 Weiao Pharmaceutical (Sichuan) Description and Business Overview
6.12.3 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio
6.12.5 Weiao Pharmaceutical (Sichuan) Recent Developments/Updates
6.13 Zhejiang Medicine
6.13.1 Zhejiang Medicine Company Information
6.13.2 Zhejiang Medicine Description and Business Overview
6.13.3 Zhejiang Medicine α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio
6.13.5 Zhejiang Medicine Recent Developments/Updates
6.14 Cisen Pharmaceutical
6.14.1 Cisen Pharmaceutical Company Information
6.14.2 Cisen Pharmaceutical Description and Business Overview
6.14.3 Cisen Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.14.5 Cisen Pharmaceutical Recent Developments/Updates
6.15 Zhejiang Jingxin Pharmaceutical
6.15.1 Zhejiang Jingxin Pharmaceutical Company Information
6.15.2 Zhejiang Jingxin Pharmaceutical Description and Business Overview
6.15.3 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.15.5 Zhejiang Jingxin Pharmaceutical Recent Developments/Updates
6.16 Nanjing Hicin Pharmaceutical
6.16.1 Nanjing Hicin Pharmaceutical Company Information
6.16.2 Nanjing Hicin Pharmaceutical Description and Business Overview
6.16.3 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.16.5 Nanjing Hicin Pharmaceutical Recent Developments/Updates
6.17 Beijing SL Pharmaceutical
6.17.1 Beijing SL Pharmaceutical Company Information
6.17.2 Beijing SL Pharmaceutical Description and Business Overview
6.17.3 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.17.5 Beijing SL Pharmaceutical Recent Developments/Updates
6.18 Jinri Pharmaceutical (China)
6.18.1 Jinri Pharmaceutical (China) Company Information
6.18.2 Jinri Pharmaceutical (China) Description and Business Overview
6.18.3 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio
6.18.5 Jinri Pharmaceutical (China) Recent Developments/Updates
6.19 Hangzhou East China Pharmaceutical
6.19.1 Hangzhou East China Pharmaceutical Company Information
6.19.2 Hangzhou East China Pharmaceutical Description and Business Overview
6.19.3 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.19.5 Hangzhou East China Pharmaceutical Recent Developments/Updates
6.20 Zhejiang Hisun Pharmaceutical
6.20.1 Zhejiang Hisun Pharmaceutical Company Information
6.20.2 Zhejiang Hisun Pharmaceutical Description and Business Overview
6.20.3 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.20.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
6.21 CSPC Ouyi Pharmaceutical
6.21.1 CSPC Ouyi Pharmaceutical Company Information
6.21.2 CSPC Ouyi Pharmaceutical Description and Business Overview
6.21.3 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.21.4 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
6.21.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
6.22 Luye Pharma
6.22.1 Luye Pharma Company Information
6.22.2 Luye Pharma Description and Business Overview
6.22.3 Luye Pharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Luye Pharma α-Glucosidase Inhibitors Product Portfolio
6.22.5 Luye Pharma Recent Developments/Updates
6.23 Livzon Pharm
6.23.1 Livzon Pharm Company Information
6.23.2 Livzon Pharm Description and Business Overview
6.23.3 Livzon Pharm α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Livzon Pharm α-Glucosidase Inhibitors Product Portfolio
6.23.5 Livzon Pharm Recent Developments/Updates
6.24 YaoPharma
6.24.1 YaoPharma Company Information
6.24.2 YaoPharma Description and Business Overview
6.24.3 YaoPharma α-Glucosidase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.24.4 YaoPharma α-Glucosidase Inhibitors Product Portfolio
6.24.5 YaoPharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 α-Glucosidase Inhibitors Industry Chain Analysis
7.2 α-Glucosidase Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 α-Glucosidase Inhibitors Production Mode & Process
7.4 α-Glucosidase Inhibitors Sales and Marketing
7.4.1 α-Glucosidase Inhibitors Sales Channels
7.4.2 α-Glucosidase Inhibitors Distributors
7.5 α-Glucosidase Inhibitors Customers
8 α-Glucosidase Inhibitors Market Dynamics
8.1 α-Glucosidase Inhibitors Industry Trends
8.2 α-Glucosidase Inhibitors Market Drivers
8.3 α-Glucosidase Inhibitors Market Challenges
8.4 α-Glucosidase Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global α-Glucosidase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global α-Glucosidase Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global α-Glucosidase Inhibitors Market Competitive Situation by Manufacturers in 2023
 Table 4. Global α-Glucosidase Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global α-Glucosidase Inhibitors Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global α-Glucosidase Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global α-Glucosidase Inhibitors Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market α-Glucosidase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of α-Glucosidase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of α-Glucosidase Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of α-Glucosidase Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of α-Glucosidase Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global α-Glucosidase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in α-Glucosidase Inhibitors as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global α-Glucosidase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global α-Glucosidase Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 18. Global α-Glucosidase Inhibitors Sales Market Share by Region (2019-2024)
 Table 19. Global α-Glucosidase Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 20. Global α-Glucosidase Inhibitors Sales Market Share by Region (2025-2030)
 Table 21. Global α-Glucosidase Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global α-Glucosidase Inhibitors Revenue Market Share by Region (2019-2024)
 Table 23. Global α-Glucosidase Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global α-Glucosidase Inhibitors Revenue Market Share by Region (2025-2030)
 Table 25. North America α-Glucosidase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America α-Glucosidase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 27. North America α-Glucosidase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 28. North America α-Glucosidase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America α-Glucosidase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe α-Glucosidase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe α-Glucosidase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 32. Europe α-Glucosidase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 33. Europe α-Glucosidase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe α-Glucosidase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific α-Glucosidase Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific α-Glucosidase Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific α-Glucosidase Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific α-Glucosidase Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific α-Glucosidase Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America α-Glucosidase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America α-Glucosidase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America α-Glucosidase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America α-Glucosidase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America α-Glucosidase Inhibitors Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa α-Glucosidase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa α-Glucosidase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa α-Glucosidase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa α-Glucosidase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa α-Glucosidase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global α-Glucosidase Inhibitors Sales (K Units) by Type (2019-2024)
 Table 51. Global α-Glucosidase Inhibitors Sales (K Units) by Type (2025-2030)
 Table 52. Global α-Glucosidase Inhibitors Sales Market Share by Type (2019-2024)
 Table 53. Global α-Glucosidase Inhibitors Sales Market Share by Type (2025-2030)
 Table 54. Global α-Glucosidase Inhibitors Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global α-Glucosidase Inhibitors Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global α-Glucosidase Inhibitors Revenue Market Share by Type (2019-2024)
 Table 57. Global α-Glucosidase Inhibitors Revenue Market Share by Type (2025-2030)
 Table 58. Global α-Glucosidase Inhibitors Price (US$/Unit) by Type (2019-2024)
 Table 59. Global α-Glucosidase Inhibitors Price (US$/Unit) by Type (2025-2030)
 Table 60. Global α-Glucosidase Inhibitors Sales (K Units) by Application (2019-2024)
 Table 61. Global α-Glucosidase Inhibitors Sales (K Units) by Application (2025-2030)
 Table 62. Global α-Glucosidase Inhibitors Sales Market Share by Application (2019-2024)
 Table 63. Global α-Glucosidase Inhibitors Sales Market Share by Application (2025-2030)
 Table 64. Global α-Glucosidase Inhibitors Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global α-Glucosidase Inhibitors Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global α-Glucosidase Inhibitors Revenue Market Share by Application (2019-2024)
 Table 67. Global α-Glucosidase Inhibitors Revenue Market Share by Application (2025-2030)
 Table 68. Global α-Glucosidase Inhibitors Price (US$/Unit) by Application (2019-2024)
 Table 69. Global α-Glucosidase Inhibitors Price (US$/Unit) by Application (2025-2030)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Bayer α-Glucosidase Inhibitors Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Bluepharma Company Information
 Table 76. Bluepharma Description and Business Overview
 Table 77. Bluepharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Bluepharma α-Glucosidase Inhibitors Product
 Table 79. Bluepharma Recent Developments/Updates
 Table 80. Strides Pharma Company Information
 Table 81. Strides Pharma Description and Business Overview
 Table 82. Strides Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Strides Pharma α-Glucosidase Inhibitors Product
 Table 84. Strides Pharma Recent Developments/Updates
 Table 85. Sun Pharmaceutical Company Information
 Table 86. Sun Pharmaceutical Description and Business Overview
 Table 87. Sun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Sun Pharmaceutical α-Glucosidase Inhibitors Product
 Table 89. Sun Pharmaceutical Recent Developments/Updates
 Table 90. Takeda Company Information
 Table 91. Takeda Description and Business Overview
 Table 92. Takeda α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Takeda α-Glucosidase Inhibitors Product
 Table 94. Takeda Recent Developments/Updates
 Table 95. Pfizer Company Information
 Table 96. Pfizer Description and Business Overview
 Table 97. Pfizer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Pfizer α-Glucosidase Inhibitors Product
 Table 99. Pfizer Recent Developments/Updates
 Table 100. Lunan Pharma Company Information
 Table 101. Lunan Pharma Description and Business Overview
 Table 102. Lunan Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Lunan Pharma α-Glucosidase Inhibitors Product
 Table 104. Lunan Pharma Recent Developments/Updates
 Table 105. SUN Pharma Company Information
 Table 106. SUN Pharma Description and Business Overview
 Table 107. SUN Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. SUN Pharma α-Glucosidase Inhibitors Product
 Table 109. SUN Pharma Recent Developments/Updates
 Table 110. Lupin Pharma Company Information
 Table 111. Lupin Pharma Description and Business Overview
 Table 112. Lupin Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Lupin Pharma α-Glucosidase Inhibitors Product
 Table 114. Lupin Pharma Recent Developments/Updates
 Table 115. Glenmark Pharma Company Information
 Table 116. Glenmark Pharma Description and Business Overview
 Table 117. Glenmark Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Glenmark Pharma α-Glucosidase Inhibitors Product
 Table 119. Glenmark Pharma Recent Developments/Updates
 Table 120. Shandong New Time Pharmaceutical Company Information
 Table 121. Shandong New Time Pharmaceutical Description and Business Overview
 Table 122. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product
 Table 124. Shandong New Time Pharmaceutical Recent Developments/Updates
 Table 125. Weiao Pharmaceutical (Sichuan) Company Information
 Table 126. Weiao Pharmaceutical (Sichuan) Description and Business Overview
 Table 127. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product
 Table 129. Weiao Pharmaceutical (Sichuan) Recent Developments/Updates
 Table 130. Zhejiang Medicine Company Information
 Table 131. Zhejiang Medicine Description and Business Overview
 Table 132. Zhejiang Medicine α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Zhejiang Medicine α-Glucosidase Inhibitors Product
 Table 134. Zhejiang Medicine Recent Developments/Updates
 Table 135. Cisen Pharmaceutical Company Information
 Table 136. Cisen Pharmaceutical Description and Business Overview
 Table 137. Cisen Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. Cisen Pharmaceutical α-Glucosidase Inhibitors Product
 Table 139. Cisen Pharmaceutical Recent Developments/Updates
 Table 140. Zhejiang Jingxin Pharmaceutical Company Information
 Table 141. Zhejiang Jingxin Pharmaceutical Description and Business Overview
 Table 142. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product
 Table 144. Zhejiang Jingxin Pharmaceutical Recent Developments/Updates
 Table 145. Nanjing Hicin Pharmaceutical Company Information
 Table 146. Nanjing Hicin Pharmaceutical Description and Business Overview
 Table 147. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product
 Table 149. Nanjing Hicin Pharmaceutical Recent Developments/Updates
 Table 150. Beijing SL Pharmaceutical Company Information
 Table 151. Beijing SL Pharmaceutical Description and Business Overview
 Table 152. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product
 Table 154. Beijing SL Pharmaceutical Recent Developments/Updates
 Table 155. Jinri Pharmaceutical (China) Company Information
 Table 156. Jinri Pharmaceutical (China) Description and Business Overview
 Table 157. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product
 Table 159. Jinri Pharmaceutical (China) Recent Developments/Updates
 Table 160. Hangzhou East China Pharmaceutical Company Information
 Table 161. Hangzhou East China Pharmaceutical Description and Business Overview
 Table 162. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product
 Table 164. Hangzhou East China Pharmaceutical Recent Developments/Updates
 Table 165. Zhejiang Hisun Pharmaceutical Company Information
 Table 166. Zhejiang Hisun Pharmaceutical Description and Business Overview
 Table 167. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 168. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product
 Table 169. Zhejiang Hisun Pharmaceutical Recent Developments/Updates
 Table 170. CSPC Ouyi Pharmaceutical Company Information
 Table 171. CSPC Ouyi Pharmaceutical Description and Business Overview
 Table 172. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 173. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product
 Table 174. CSPC Ouyi Pharmaceutical Recent Developments/Updates
 Table 175. Luye Pharma Company Information
 Table 176. Luye Pharma Description and Business Overview
 Table 177. Luye Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 178. Luye Pharma α-Glucosidase Inhibitors Product
 Table 179. Luye Pharma Recent Developments/Updates
 Table 180. Livzon Pharm Company Information
 Table 181. Livzon Pharm Description and Business Overview
 Table 182. Livzon Pharm α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 183. Livzon Pharm α-Glucosidase Inhibitors Product
 Table 184. Livzon Pharm Recent Developments/Updates
 Table 185. YaoPharma Company Information
 Table 186. YaoPharma Description and Business Overview
 Table 187. YaoPharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 188. YaoPharma α-Glucosidase Inhibitors Product
 Table 189. YaoPharma Recent Developments/Updates
 Table 190. Key Raw Materials Lists
 Table 191. Raw Materials Key Suppliers Lists
 Table 192. α-Glucosidase Inhibitors Distributors List
 Table 193. α-Glucosidase Inhibitors Customers List
 Table 194. α-Glucosidase Inhibitors Market Trends
 Table 195. α-Glucosidase Inhibitors Market Drivers
 Table 196. α-Glucosidase Inhibitors Market Challenges
 Table 197. α-Glucosidase Inhibitors Market Restraints
 Table 198. Research Programs/Design for This Report
 Table 199. Key Data Information from Secondary Sources
 Table 200. Key Data Information from Primary Sources
 Table 201. Authors List of This Report


List of Figures
 Figure 1. Product Picture of α-Glucosidase Inhibitors
 Figure 2. Global α-Glucosidase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global α-Glucosidase Inhibitors Market Share by Type: 2023 & 2030
 Figure 4. Acarbose Product Picture
 Figure 5. Voglibose Product Picture
 Figure 6. Miglitol Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global α-Glucosidase Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global α-Glucosidase Inhibitors Market Share by Application: 2023 & 2030
 Figure 10. Hospital and Clinic
 Figure 11. Pharmacy
 Figure 12. Other
 Figure 13. Global α-Glucosidase Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global α-Glucosidase Inhibitors Market Size (2019-2030) & (US$ Million)
 Figure 15. Global α-Glucosidase Inhibitors Sales (2019-2030) & (K Units)
 Figure 16. Global α-Glucosidase Inhibitors Average Price (US$/Unit) & (2019-2030)
 Figure 17. α-Glucosidase Inhibitors Report Years Considered
 Figure 18. α-Glucosidase Inhibitors Sales Share by Manufacturers in 2023
 Figure 19. Global α-Glucosidase Inhibitors Revenue Share by Manufacturers in 2023
 Figure 20. Global 5 and 10 Largest α-Glucosidase Inhibitors Players: Market Share by Revenue in α-Glucosidase Inhibitors in 2023
 Figure 21. α-Glucosidase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 22. Global α-Glucosidase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 23. North America α-Glucosidase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 24. North America α-Glucosidase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 25. United States α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Canada α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Europe α-Glucosidase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 28. Europe α-Glucosidase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 29. Germany α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. France α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. U.K. α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Italy α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Russia α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Asia Pacific α-Glucosidase Inhibitors Sales Market Share by Region (2019-2030)
 Figure 35. Asia Pacific α-Glucosidase Inhibitors Revenue Market Share by Region (2019-2030)
 Figure 36. China α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Japan α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. South Korea α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. India α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Australia α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. China Taiwan α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Southeast Asia α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Latin America α-Glucosidase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 44. Mexico α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Brazil α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Argentina α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Colombia α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Middle East and Africa α-Glucosidase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 49. Middle East and Africa α-Glucosidase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 50. Turkey α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Saudi Arabia α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. UAE α-Glucosidase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Global Sales Market Share of α-Glucosidase Inhibitors by Type (2019-2030)
 Figure 54. Global Revenue Market Share of α-Glucosidase Inhibitors by Type (2019-2030)
 Figure 55. Global α-Glucosidase Inhibitors Price (US$/Unit) by Type (2019-2030)
 Figure 56. Global Sales Market Share of α-Glucosidase Inhibitors by Application (2019-2030)
 Figure 57. Global Revenue Market Share of α-Glucosidase Inhibitors by Application (2019-2030)
 Figure 58. Global α-Glucosidase Inhibitors Price (US$/Unit) by Application (2019-2030)
 Figure 59. α-Glucosidase Inhibitors Value Chain
 Figure 60. α-Glucosidase Inhibitors Production Process
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS